CAR‑X's manifest destiny #substack #shorts

19 May 2026 · 1 min

Watch on YouTube

0:44

In this short dialogue, Speaker A outlines the current state and future direction of CAR‑X (chimeric antigen receptor) cell therapies. The conversation explains that today’s standard process involves extracting a patient’s white blood cells via plasmapheresis, cryopreserving them, shipping them to a central facility for genetic engineering, then freezing and returning them for infusion—a logistically complex and biologically stressful pipeline. Speaker A argues that the technology’s “manifest destiny” is to shift toward in‑body manufacturing, where viral vectors or nanoparticles are injected to reprogram cells directly inside the patient, leveraging the body’s own cellular production capacity. Speaker B notes the need for extensive equipment to support the current ex‑vivo workflow. As an intermediate step, Speaker A mentions a hospital‑based manufacturing device that would keep the process on‑site, eliminating long‑distance shipping and repeated freezing, and notes that one of their investments is pursuing this solution. The overall tone is technical yet conversational, with a cautiously optimistic view of in‑vivo approaches and supportive sentiment toward near‑term hospital devices.

Chapters

AI. Yeah, I was going to say AI is not a micro bubble. It's a whole kettle of fish. I would say maybe— I think CAR-T is going through many different— and I should say CAR-X, chimeric antigen receptor. T cells are one thing, but it can be macrophages. It's being used in all sorts of cells. There's a move to go from making those outside the body to inside the body. So, can you inject the virus or the nanoparticles that'll transform those cells into be the cells you want? And I think that's probably the manifest destiny of that technology. It just makes way more sense. Your body already makes cells.
Well, you need all these machinery to send blood out to do stuff to then send it back to the body.
Yeah. Yeah. There's that as well. State of the art is you do plasmapheresis and get somebody's white blood cells, freeze them, which is not good for them, FedEx them, as it were, to a central facility, do the magic, freeze them again, send them back, and infuse them. And in the meantime, that person is really cutting the cord from their parachute and hoping to intercept your therapy. There's a halfway step is building a device that is in the hospital, for instance, right? So you don't have to send it out. You don't have to freeze it. It would go down to the basement. There'd be a nice clean area for it, a dedicated laboratory. One of our investments is doing something along those lines.